pharma · Recipients of allogeneic stem cell transplantation
AstraZeneca
Astra Zeneca AB
NovaPharmaNews editorial coverage mentioning AstraZeneca — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- cambridge, GB
- Employees
- 79,242
- Programs
- 1
- Drugs
- 8
- Patents
- 25
News & analysis
NovaPharmaNews articles mentioning AstraZeneca — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning AstraZeneca — regulatory, clinical, and market analysis.
Owkin and AstraZeneca Enhance AI Collaboration for Drug Research
Owkin and AstraZeneca have expanded their collaboration to develop AI-driven drug research tools, aiming to accelerate clinical trials and reduce costs. This deal intelligence article provides key takeaways, regulatory implications, and an FAQ section for pharma teams and investors.
AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma
The FDA approved AstraZeneca and Daiichi Sankyo's Datroway (Dato-DXd) as a first-line treatment for triple-negative breast cancer on May 1, 2026. This article provides key takeaways, regulatory details, and strategic implications for pharma decision-makers.